Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty

• Status: Completed
• Trial end date: 2020-12-20
• Target enrollment: 0
• Participant gender: All

Summary

Primary aim of the study is to determine whether a rho kinase inhibitor, Netarsudil, can speed corneal clearance after DWEK. Secondary aim of the study is to investigate whether patient factors, such as baseline age, pachymetry, or endothelial cell count influence response to Netarsudil.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts Eye and Ear Infirmary
• Treatments: Ophthalmic Solutions

Criteria

Inclusion Criteria:

• Cataract in both eyes

• Fuchs endothelial dystrophy in both eyes

Exclusion Criteria:

• History of ocular surgery in one eye and not the other

• History of significant ocular trauma/burn in one eye and not the other

• Inability to provide informed consent

• Inability to undergo eye surgery

• Inablity to use eye drops reliably